Real-World Meta-Analysis Confirms Galcanezumab Efficacy in Migraine Prevention Across 3,859 Patients
核心洞察
A comprehensive meta-analysis of 36 real-world studies involving 3,859 patients demonstrated that galcanezumab significantly reduced monthly migraine (搜索) days by 6.93 to 10.90 days and monthly headache days by 8.55 to 10.97 days over 12 months of treatment.
Approximately two-thirds of patients achieved at least a 50% reduction in monthly migraine (搜索) or headache days within 3-6 months, with one-third achieving at least a 75% response rate.
The CGRP-blocking medication maintained a favorable safety profile with adverse events occurring in 23-35% of patients, primarily mild constipation, confirming its potential as an effective migraine (搜索) management option in clinical practice.
A large-scale meta-analysis of real-world studies has provided robust evidence supporting the efficacy and safety of galcanezumab (Emgality; Eli Lilly) for migraine (搜索) prevention, analyzing data from 36 studies encompassing 3,859 patients with chronic or episodic migraine (搜索). The findings, published in Headache, demonstrate substantial reductions in migraine frequency and functional disability measures while maintaining a favorable safety profile.
Significant Reductions in Migraine Frequency
The analysis revealed progressive improvements in migraine (搜索) control across the 12-month treatment period. Monthly migraine days (MMD) decreased by 6.93 days at one month, progressively improving to 10.90 days at 12 months. Similarly, monthly headache days (MHD) showed reductions ranging from 8.55 days at one month to 10.97 days at 12 months.
Led by Jaime Fernández-Bravo-Rodrigo, PharmD, a hospital pharmacy specialist at the Virgen del Castillo Hospital in Yecla, the research team conducted a systematic search of databases including PubMed, Scopus, and Web of Science from inception to February 2025. The final analysis included 19 prospective, 16 retrospective, and one cross-sectional study conducted primarily in European countries, with additional investigations from Asia, Brazil, Australia, and the United States.
Functional Improvements and Response Rates
Beyond migraine (搜索) frequency reduction, patients experienced substantial improvements in functional measures. Headache Impact Test-6 scores declined by 7.96 to 11.97 points across the 12-month period, while Migraine Disability Assessment Scale (MIDAS) scores showed reductions of 42.61 points at 3 months and 50.52 to 55.17 points from 6 to 12 months.
The study population included patients with a mean age ranging from 35.5 to 69.8 years, with 80.17% having chronic migraine (搜索), 81.4% being women, and 60.9% having a history of medication overuse. Despite this diverse and challenging patient population, clinically meaningful response rates were achieved.
Approximately two-thirds of patients achieved at least a 50% response rate in MMD or MHD at 3 to 6 months, while one-third achieved at least a 75% response rate. Complete response was observed in 2% to 7% of patients, representing significant clinical improvement for individuals with previously treatment-resistant migraine (搜索).
Reduced Acute Medication Dependence
The analysis also demonstrated substantial reductions in acute medication usage. Days requiring acute migraine (搜索)-specific medication decreased by 6.79 to 13.01 days, while acute monthly intake fell by 11.85 to 19.35 units across the treatment period. Pain intensity scores declined by 1.67 to 2.29 points from 3 to 12 months, indicating meaningful improvements in symptom severity.
Safety Profile and Adverse Events
The safety analysis revealed a generally well-tolerated profile. The pooled prevalence of any adverse event was 0.23 (95% CI, 0.07-0.44) at 3 months, 0.25 (95% CI, 0.14-0.38) at 6 months, and 0.35 (95% CI, 0.27-0.45) at 12 months. Constipation emerged as the most commonly reported adverse event, with pooled prevalence estimates of 0.06 (95% CI, 0.02-0.11) at 3 months and 0.16 (95% CI, 0.06-0.29) at 6 months.
Senior author Ivan Cavero-Redondo, PhD, of the Faculty of Nursing at University of Castilla-La Mancha, and colleagues noted that adverse events were generally mild and occurred at low rates, supporting the medication's tolerability in real-world clinical practice.
Factors Influencing Treatment Response
Metaregression analyses revealed several factors associated with treatment response. Higher baseline outcome values were linked to greater absolute reductions in MMD, MIDAS scores, medication days, and acute medication intake. However, medication overuse showed negative associations with improvements in MIDAS scores at 9 and 12 months, while female sex was associated with smaller treatment effects for MMD across all time points.
Geographic variations were also observed, with European studies demonstrating slightly greater reductions in several outcomes compared with non-European populations. The authors noted that episodic migraine (搜索) had no significant effect on treatment outcomes.
Clinical Implications and Future Directions
The researchers acknowledged several limitations, including the absence of control groups in the majority of studies and considerable heterogeneity across outcomes. The high heterogeneity observed across studies limits the certainty of evidence, underscoring the need for additional high-quality, controlled comparative research.
Despite these limitations, Cavero-Redondo and colleagues concluded: "Galcanezumab may play a key role in the management of migraine (搜索) in clinical practice, providing effective and well-tolerated treatment. Importantly, it offers a therapeutic option for patients with multiple comorbidities or a high baseline disease burden, improving quality of life by alleviating migraine and reducing the need for acute medication."
Galcanezumab, approved by the FDA in September 2018 for migraine (搜索) prevention, is the only CGRP monoclonal antibody with demonstrated response rates of 50%, 75%, and 100% reduction from baseline in monthly migraine headache days over 1 to 6 months in adults with episodic migraine (搜索). The FDA expanded its indication in June 2019 to include treatment of episodic cluster headache (搜索).